Market closed
AnaptysBio/$ANAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About AnaptysBio
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Ticker
$ANAB
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
136
Website
AnaptysBio Metrics
BasicAdvanced
$630M
-
-$5.12
0.02
-
Price and volume
Market cap
$630M
Beta
0.02
52-week high
$41.31
52-week low
$12.21
Average daily volume
918K
Financial strength
Current ratio
9.507
Quick ratio
9.381
Long term debt to equity
518.623
Total debt to equity
521.34
Interest coverage (TTM)
-2.29%
Management effectiveness
Return on assets (TTM)
-15.35%
Return on equity (TTM)
-182.71%
Valuation
Price to revenue (TTM)
6.39
Price to book
8.84
Price to tangible book (TTM)
8.84
Price to free cash flow (TTM)
-4.298
Growth
Revenue change (TTM)
432.03%
Earnings per share change (TTM)
-15.80%
3-year revenue growth (CAGR)
13.05%
3-year earnings per share growth (CAGR)
34.42%
What the Analysts think about AnaptysBio
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for AnaptysBio stock.
AnaptysBio Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
AnaptysBio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
AnaptysBio News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for AnaptysBio stock?
AnaptysBio (ANAB) has a market cap of $630M as of April 20, 2025.
What is the P/E ratio for AnaptysBio stock?
The price to earnings (P/E) ratio for AnaptysBio (ANAB) stock is 0 as of April 20, 2025.
Does AnaptysBio stock pay dividends?
No, AnaptysBio (ANAB) stock does not pay dividends to its shareholders as of April 20, 2025.
When is the next AnaptysBio dividend payment date?
AnaptysBio (ANAB) stock does not pay dividends to its shareholders.
What is the beta indicator for AnaptysBio?
AnaptysBio (ANAB) has a beta rating of 0.02. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.